Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



To whom it may concern

May 14, 2025

Company Name	Y.A.C. HOLDINGS, CO., LTD.
Representative	MOMOSE Takefumi
	Representative Director,
	Chairman and President
	(Code No. 6298 TSE Prime)
Inquiries	HATAKEYAMA Osamu
	Director & Senior General Manager,
	Administration Headquarters
	(Tel +81-42-546-1161)

Notice regarding partial changes to "Notice of Establishment of Joint Venture **Company with LINUS BIOTECHNOLOGY, INC.**"

We (hereinafter "The company") hereby announce that some corrections have been made to the "Notice of Establishment of Joint Venture with LINUS BIOTECHNOLOGY, INC." which was announced on November 14, 2024, as detailed below.

Details are as follows.

[Background of the corrections and upcoming plan]

- 1. At the Board of Directors meeting held on November 14, 2024, the company resolved to establish a joint venture company in Japan between our wholly owned subsidiary "YAC BIO, INC. (hereinafter "YAC BIO")" and "LINUS BIOTECNOLOGY, INC. (hereinafter "LinusBio")", and the timely disclosure of this decision was made on the same day.
- 2. Subsequently, the detailed coordination with parties concerned regarding various agreements, including the joint venture agreement, has taken longer than expected, resulting in schedule delays.
- 3. Until the joint venture company is established, hair-based autism analysis services in Japan will be provided in collaboration with LinusBio. Specifically, YAC BIO will be responsible for hair sample collection and promotion, while data analysis will be managed by LinusBio, and the hair-based autism analysis services in Japan are scheduled to launch around July 2025.

<Before correction> November 14, 2024 (1) Date of resolution by the Board of Directors (2) Date of Joint Venture Agreement Late November 2024 *A basic agreement on the establishment of the company was exchanged on November 19, 2024. (3) Date of Incorporation Early December 2024 (to be determined) March 2025 (estimated) (4) Business start date

[Correction details] : 4. Schedule

<after correction=""></after>	
(1) Date of resolution by the Board	November 14, 2024
of Directors	
(2) Date of Joint Venture Agreement	Under Negotiation (Note 1)
	XA basic agreement on the establishment of the company
	was exchanged on November 19, 2024.
(3) Date of Incorporation	Under Negotiation (Note 1)
(4) Business start date	Under Negotiation (Note 2)

(Note 1) Negotiations are underway to conclude an agreement by August 2025.

(Note 2) In the period leading up to the establishment of the joint venture, YAC Bio will provide autism analysis services in Japan in collaboration with LinusBio.

[Affect]

The corrections will not affect our consolidated financial results for the fiscal year ending March 2025. We will carefully examine the impact on our consolidated financial results forecast for the fiscal year ending March 2026 and disclose relevant information in a timely manner.

-end-

[For inquiries regarding this matter, please contact]

Management Promotion Department, Corporate Strategy Division TeL : +81-42-546-1161 mail: yac_ir@yac.co.jp